Search Results
Your search for it matches 15610 pages
Showing 2651 - 2700Study Investigates Rural/Urban Disparities in Hospice Care Among Patients With Hematologic Malignancies
People with blood cancers living in rural areas are less likely to receive end-of-life hospice care compared to those living in metropolitan regions, according to a new study published by Hussaini et al in the journal Blood Advances. In this study, researchers identified significant disparities in...
FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children as Young as 6 Months of Age
On June 17, the U.S. Food and Drug Administration (FDA) authorized emergency use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include use in children as young as 6 months of age. For the Moderna vaccine, the FDA amended the emergency...
Postmarketing Ocular Toxicity in U.S. Adults Treated With Daratumumab
In an analysis reported in a research letter in JAMA Oncology, Nguyen et al identified postmarketing cases of ocular toxicity in patients receiving daratumumab in the United States. Daratumumab is a CD38-directed monoclonal antibody that was initially approved in 2015 for the treatment of multiple...
Elevating Cancer Care in the United States for All: Current Challenges and Potential Solutions
Optimizing oncology care in the United States will require making state-of-the-art care more accessible to all. Delivering quality, equitable cancer care is undoubtedly a challenge in a country as large, diverse, and disparate as the United States, but if it is to be achieved, it will entail the...
Study Finds Adult Survivors of Childhood Cancer May Often Be Undertreated for Modifiable Cardiovascular Risk Factors
Adults who survive childhood cancer have a higher risk of cardiovascular disease than the general population, yet they are 80% more likely to be undertreated for several cardiovascular risk factors, such as hypertension, diabetes, and high cholesterol, according to new research published by Eric J. ...
Risk of Skin Desquamation With Breast Radiotherapy: Does Position Change Outcomes in Large-Breasted Women?
In a Canadian phase III trial reported in JAMA Oncology, Vesprini et al found that receipt of adjuvant breast radiotherapy in the supine position was associated with increased risk of moist desquamation of skin vs receipt in the prone position among large-breasted women with breast cancer. Study...
Ursula A. Matulonis, MD, and Domenica Lorusso, MD, PhD, on Gynecologic Cancers: New Findings on Trabectedin vs Clinician’s Choice Chemotherapy
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Domenica Lorusso, MD, PhD, of Italy’s Gemelli University Hospital, discuss phase III data from the MITO23 trial on single-agent trabectedin vs clinician’s choice of chemotherapy in patients with recurrent ovarian, primary peritoneal, or...
Nancy Davidson, MD: In It for the Long Haul: Outcomes in Hormone Receptor–Positive Breast Cancer
Nancy Davidson, MD, of the Fred Hutchinson Cancer Research Center, reviews results from four abstracts about the importance of long-term follow-up in studies of adjuvant endocrine therapy for hormone receptor–positive breast cancer. Because the natural history of hormone receptor–positive breast...
Ralph Lauren Corporate Foundation Announces $25 Million Commitment to Five U.S. Cancer Centers to Help Reduce Disparities in Cancer Care in Underserved Communities
The Ralph Lauren Corporate Foundation recently announced it will provide $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities in the United States. The funding will benefit...
Fred Hutch, SCCA, Seattle Children’s, and UW Medicine Complete Restructure of Partnership
Fred Hutchinson Cancer Research Center (Fred Hutch), Seattle Cancer Care Alliance (SCCA), Seattle Children’s, and the University of Washington (UW) Medicine have completed the restructure of their longtime relationship and the formation of Fred Hutchinson Cancer Center, a unified adult cancer...
TJ Gan, MD, FRCA (UK), to Join MD Anderson as Division Head of Anesthesiology, Critical Care and Pain Medicine
The University of Texas MD Anderson Cancer Center recently announced that Tong Joo (TJ) Gan, MD, FRCA (UK), has been named Division Head of Anesthesiology, Critical Care and Pain Medicine. Dr. Gan will join MD Anderson’s faculty on September 1. Dr. Gan will lead a division composed of 117 faculty...
Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Remission 10 Years Later
Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) 10 years ago looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so...
Annual Meeting of the Moroccan Cancer Society: An Opportunity for Young Cancer Researchers to Evolve
The Moroccan Cancer Society (MCS; Société Marocaine de Cancérologie/https://smc.ma) was created in 1992 by a group of Moroccan medical and radiation oncologists, surgeons, and pathologists who had led the field in the 1980s. To date, this scientific society has more than 350 members practicing in...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
Use of T-DXd in Previously Treated Patients With Advanced HER2-Positive Breast Cancer
On May 4, 2022, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted regular approval for patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2–based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed...
Traditional Chinese Medicine Herbal Formula Ma Zi Ren Wan for Constipation
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Eugenie Spiguel, MSN, ANP-BS, and Jyothirmai Gubili, MS, focus on Ma Zi Ren...
How Social Media Is Fueling an Epidemic of Misinformation and Disinformation—and Distrust in Science
The COVID-19 pandemic and the confluence of events that followed—including the rapid development of vaccines, the mixed messaging on mitigation efforts to prevent coronavirus infection, and the growing political polarization—helped spark public mistrust and skepticism toward science. This mistrust...
NCCN Honors Oncology Leaders Promoting Progress in Cancer Care
The National Comprehensive Cancer Network® (NCCN®) recently announced the recipients of 2022 awards for both internal and external champions advancing NCCN’s mission and helping all people with cancer to live better lives. The annual awards include the Rodger Winn Award for expert judgment and...
Cemiplimab-rwlc Following Platinum-Based Chemotherapy in Recurrent or Metastatic Cervical Cancer: Clinical Implications
It is estimated that globally, more than 600,000 women per year are diagnosed with cervical cancer, and more than 300,000 die annually of the disease.1 Many women continue to be diagnosed with cervical cancer at an advanced stage, with a high risk of recurrence. To date, the most effective...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the BEGONIA trial,1 Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, called the activity of the combination of durvalumab and datopotamab deruxtecan (Dato-DXd) “notable,” with a 74% response rate overall,...
BEGONIA Trial Reports Activity With Datopotamab Deruxtecan Plus Durvalumab in Triple-Negative Breast Cancer
Preliminary results of the basket BEGONIA trial showed that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), paired with the immune checkpoint inhibitor durvalumab, has strong activity in advanced or metastatic triple-negative breast cancer among patients not biomarker-selected for...
DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer?
Since the introduction of trastuzumab in the late 1990s, overall survival for patients with HER2-positive metastatic breast cancer has substantially improved. Median overall survival in the pivotal first-line trial was only 20.3 months in the chemotherapy arm, and 25.1 months in the...
Momelotinib for Symptomatic and Anemic Patients With Myelofibrosis
Once-daily treatment with the oral JAK1/2 and ACVR1/ALK2 inhibitor momelotinib significantly improved outcomes of patients treated for myelofibrosis. Ruben Mesa, MD, FACP, and colleagues presented results of the MOMENTUM phase III randomized study, which evaluated momelotinib vs danazol in...
FDA Approves FoundationOne CDx as a Companion Diagnostic for Entrectinib
On June 9, Foundation Medicine, Inc., announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne CDx to be used as a companion diagnostic for the two indications of the tyrosine kinase inhibitor entrectinib (Rozlytrek). As a companion diagnostic,...
Tara B. Sanft, MD, on How Diet and Exercise May Affect Completion of Chemotherapy for Breast Cancer
Tara B. Sanft, MD, of Yale University, discusses the results of the LEANer study (Lifestyle, Exercise, and Nutrition Early After Diagnosis) in women with breast cancer. It showed that patients with newly diagnosed disease who were just starting chemotherapy could improve physical activity and diet...
Capecitabine Plus Temozolomide vs Temozolomide Alone in Advanced Pancreatic Neuroendocrine Tumors
In the updated final analysis of the phase II ECOG-ACRIN E2211 trial, patients with advanced pancreatic neuroendocrine tumors experienced a significant improvement in progression-free survival with capecitabine plus temozolomide over temozolomide alone.1 Although the 5-month difference in overall...
Weekly Electronic Reporting of Symptoms Improved Outcomes in Patients With Advanced Cancer
People with advanced cancer who communicated their symptoms weekly using an electronic survey had about one-third better physical function and over a 15% better control of their symptoms compared to those who were evaluated less frequently via in-person clinical visits, according to findings from a ...
Patient-Facing Screening Tool Could Increase Detection of Individuals With Lynch Syndrome
Nearly 1 million people in the United States are affected by Lynch syndrome, a hereditary cancer condition with markedly elevated risk of gastrointestinal, endometrial, and other cancers. Most of them, however, are unaware of it, or find out only after they have developed cancer. A screening...
Three-Arm First-Line Chemoimmunotherapy Study in Patients With Metastatic Pancreatic Cancer
Combinations of chemotherapy and immunotherapy showed activity in patients with metastatic pancreatic cancer, according to findings from a national, randomized clinical trial led and sponsored by the Parker Institute for Cancer Immunotherapy. The results of the small trial were presented by Padrón...
Study Finds Genetic Mutations Differ Across Younger and Older Patients With Breast Cancer
Women younger than age 40 with advanced breast cancer often experience more aggressive disease and worse prognoses than their older counterparts. Knowing which types of genetic mutations these patients tend to have may inform treatment strategies and improve outcomes. In a recent study, researchers ...
Did the ACA’S Medicaid Expansion Affect Cancer Clinical Trial Enrollment?
Researchers from the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), found that the Affordable Care Act’s (ACA) expansion of Medicaid insurance in 2014 was followed by a significant increase in the proportion of patients enrolling in SWOG trials...
Biomarker Guidance May Allow Patients Aged 55 or Older With Low-Grade Luminal A–Type Breast Cancer to Avoid Radiation Therapy
Based on guidance from biomarker screening, patients with low-grade luminal A–type breast cancer aged 55 and older may need endocrine therapy alone following breast-conserving surgery and may be able to avoid radiation therapy entirely, according to new research findings presented by Timothy Joseph ...
Dabrafenib Plus Trametinib Improve Overall Response Rates vs Standard-of-Care Chemotherapy in Pediatric Patients With Low-Grade Gliomas
The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600...
Study Offers Guidance for Future Trials of Adjuvant Therapy for Early-Stage Hormone Receptor–Positive/HER2-Negative Breast Cancer
To fully evaluate hormone-blocking therapy following surgery for patients with early-stage high-risk hormone receptor–positive/HER2-negative breast cancer, researchers should continue to track patients for at least 5 years after the completion of active treatment, according to a study reported at...
Including ASCT as Part of Initial Therapy Improves Progression-Free Survival in Newly Diagnosed Patients With Multiple Myeloma
The use of autologous stem cell transplantation (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed patients with multiple myeloma compared with patients who received chemotherapy without an initial...
Study Finds High-Dose Ifosfamide Superior to Other Standard-of-Care Treatments in Recurrent and Primary Refractory Ewing Sarcomas
Use of high-dose ifosfamide was found to be superior for treating recurrent and primary refractory Ewing sarcomas compared with three other standard-of-care treatments used for the disease, according to research presented by McCabe et al during the Plenary Session at the 2022 ASCO Annual Meeting...
Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast Cancer
The use of fam-trastuzumab deruxtecan-nxki doubled progression-free survival compared with the standard-of-care treatment plus conventional chemotherapy. It also significantly improved overall survival for patients with metastatic breast cancers expressing low levels of the HER2 receptor,...
Panitumumab Plus mFOLFOX6 Improves Overall Survival in a Type of Newly Diagnosed Metastatic Colorectal Cancer
The use of panitumumab plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared with patients who received mFOLFOX6 plus bevacizumab, according to findings presented during the Plenary Session by...
New Report Shows COVID-19 Pandemic Increased Cancer-Related Deaths in the United States
According to a new study led by researchers at the American Cancer Society, the COVID-19 pandemic increased the number of cancer-related deaths by 3.2% in the United States from 2019 to 2020. Compared to 2019, the monthly cancer-related mortality rate was higher in April 2020, when health-care...
ctDNA May Help Identify the Need for Adjuvant Therapy in Stage II Colon Cancer
In patients with stage II colon cancer where cancer DNA was not present in the blood (as circulating tumor DNA, or ctDNA), adjuvant chemotherapy could be skipped without compromising recurrence-free survival. Conversely, for patients where ctDNA was present after surgery, the rate of recurrence...
Sacituzumab Govitecan-hziy Improves Progression-Free Survival in Endocrine-Resistant Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy resulted in longer progression-free survival compared to physician’s choice of chemotherapy in patients who have received many prior therapies for hormone receptor–positive/HER2-negative metastatic breast cancer, according to...
Nimotuzumab May Improve Overall Survival in Patients With KRAS Wild-Type Advanced Pancreatic Cancer
The addition of nimotuzumab, an EGFR-targeting monoclonal antibody, to gemcitabine increased overall survival in patients with KRAS wild-type advanced pancreatic cancer, particularly those who did not need surgery for obstruction of a pancreatic bile duct, according to data from the phase III...
Jeremy Abramson, MD, Comments on Results From the SHINE Trial
Jeremy Abramson, MD, Director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, was enthusiastic about these data. “These important data show that ibrutinib added to bendamustine/rituximab ...
New Research Finds Computer-Assisted Colonoscopy May Identify More Precancerous Polyps Than Traditional Colonoscopy
Colonoscopies performed with computer-aided detection, or artificial intelligence (AI), saw an increase in the overall rate of detection of adenoma, or cancerous and precancerous polyps, by 27% in average-risk patients, according to new data presented by Shaukat et al at Digestive Disease Week 2022 ...
New FDA-Approved Oncology Drugs (2021–2022)
Over the past year (May 2021–May 2022), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. FAM-TRASTUZUMAB...
A Global Humanist of Heroic Proportions Who Never Lost Sight of the Wounded Living in the Shadows of Poverty
Global health crusader Paul Farmer, MD, PhD, had a wildly unconventional childhood, which helped inform his adult life as a medical humanitarian. Dr. Farmer was born in West Adams, a town that lies along the verdant valley surrounding the Hoosic River in northern Massachusetts. He was the second of ...
City of Hope’s Department of Surgery Chair Awarded 2022 Flance-Karl Award, Given by the American Surgical Association
Yuman Fong, MD, Chair of City of Hope’s Department of Surgery and Director of its Center for Surgical Innovation, has been named a recipient of the 2022 Flance-Karl Award by the American Surgical Association (ASA). The award is given annually to one surgeon in the United States who has made...
City of Hope Researcher Receives Margaret L. Kripke Legend Award for Promotion of Women in Cancer
Leslie Bernstein, PhD, Director of City of Hope’s Division of Biomarkers of Early Detection and Prevention, received the Margaret L. Kripke Legend Award for Promotion of Women in Cancer Medicine and Cancer Science. Dr. Bernstein has made a substantial mark on both science and society by...
Turning Point
On a cool, gray November morning, I took the call from a walk-in doctor about Carla, a 26-year-old woman with progressive lymphadenopathy who was refusing investigations because of severe needle phobia. Carla was willing to meet with me to discuss treatment options for a suspected diagnosis of...
An International Leader Bridges the Political Divide in the Name of Humanity and Cancer Care
Michael Silbermann, DMD, PhD, was born on January 19, 1935, in the old quarter of Acre, a northern Arab city stretching along the north end of the Bay of Haifa in present-day Israel. “Acre, which was developed more than 4,000 years ago, was one of the primary harbors of the Phoenician people....
